Nonpeptide insulin receptor agonists

a technology of insulin receptor and agonist, which is applied in the direction of instruments, peptide/protein ingredients, biocide, etc., can solve the problems of unresolved complete mechanism, non-peptide substances which can exert the effect of insulin on the receptor, and the inability to administer the hormone by injection, so as to achieve the effect of reducing blood glucos

Inactive Publication Date: 2005-12-06
TELIK INC
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0079]Mice which are standard models of Type II diabetes, db / db mice, were administered TER16998 at 10 mg / kg and 40 mg / kg, or a vehicle as a control. FIG. 8 shows the effect of this compound on the concentration of glucose in the blood of these animals. As shown in FIG. 8, 10 mg / kg to some extent and 40 mg / kg to an appreciable extent decrease blood glucose over a period of 24 hours from the time of administration.
[0080]Compounds TER17004 and TER17005, shown in FIG. 2E, replace certain azo-linkers of TER3935 with the corresponding amide linkers. These compounds are synthesized as shown in FIG. 9.

Problems solved by technology

While the recombinant production of insulin permits a less immunogenic form to be provided and assures a reliable supply of needed quantities, the necessity to administer the hormone by injection remains, due to the instability of peptides and proteins in the digestive tract.
However, to date, nonpeptide substances which can exert the effect of insulin on its receptor have eluded discovery.
However, the complete mechanism is still unresolved.
In any event, it has not as yet been possible to utilize simple molecules to provide the effect of a peptide hormone by stimulating receptor activity independently of the peptide hormone binding site.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nonpeptide insulin receptor agonists
  • Nonpeptide insulin receptor agonists
  • Nonpeptide insulin receptor agonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Apparent Effect of TER12 on Insulin Receptor Kinase Autophosphorylation

A.

[0059]This assay is a modified form of that described in Hagino, H. et al. Diabetes (1994) 43:274-280. Briefly, human insulin receptors (hIR) were partially purified from placental extracts or from cell line IM-9. The partially purified hIRs were captured into microplate wells by incubating them for 90 minutes with wells coated with a monoclonal antibody to hlR. The wells were then treated with various dose levels of insulin and / or test compounds for 15 minutes at room temperature; ATP (10 μM) was then added to permit kinase activity to proceed. After 60 minutes, the wells were washed, and then treated for 60 minutes with biotinylated antibody directed against phospho tyrosine (PY-20) and unbound materials again washed away. The wells were then incubated with a conventional streptavidin peroxidase system for 30 minutes to assess the level of phosphorylated tyrosine.

[0060]When tested in this assay, insulin gave ...

example 2

Additional Compounds with TER12-Like Activity

[0067]Using substructure searching based on the TER12 molecule, 42 candidate compounds were obtained and assayed according to the procedure of Example 1.

[0068]A sample containing TER3938, shown in FIG. 2B, also showed agonist activity. TER3938, shown in FIG. 2B and known as Direct Yellow No. 27, showed an EC50 of 8 μM in this in vitro assay; it also enhanced the activity of insulin in stimulating autophosphorylation of insulin receptor on intact IM-9 cells. In addition, a sample containing TER3935, shown in FIG. 2C, was active in the IR kinase assay.

example 3

Identification of an Active Component of TER12 and TER3938-Containing Samples

[0069]TER12 was synthesized by the reaction scheme shown in FIG. 3. TER12 synthesized using this scheme, and TER12 when extensively purified from commercial sources were active in the assays set forth in Example 1.

[0070]In addition, the sample containing TER3938, also obtained from commercial sources, when purified to 95% purity by reverse-phase HPLC, retained its activity; however, when this sample was washed with aqueous sodium carbonate, the insoluble compound shown in FIG. 2B as TER3938 was less active in the IR kinase assay; the aqueous layer, however, retained full activity. These results led to the conclusion that some of the activity shown in samples purportedly containing only TER12 and TER3938 was due to a minor component. This minor component was postulated to be Component A, which has the formula shown in FIG. 2F. Component A, obtained from commercial sources, was purified by C-18 reverse-phase ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to view more

Abstract

Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula
wherein
  • each A is independently a proton-accepting substituent;
  • each R is independently a noninterfering substituent;
  • n is 0, 1, or 2; and
  • each linker is independently an isostere of —NHCONH— or of —N═N— or of —NHCO—.
Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.

Description

TECNICAL FIELD[0001]The invention relates to the substitution of nonpeptide compounds for peptide ligands that activate hormone receptors. More specifically, it concerns simple nonpeptide compounds that behave as agonists for the insulin receptor and enhance the effect of insulin on this receptor.BACKGROUND ART[0002]Among the many functions performed by peptides and proteins in metabolism is the ability to stimulate receptors at cell surfaces to effect intracellular consequences important in maintenance and development of the organism. Peptide and protein hormones interact with receptors specific for them so that the activity of the hormone is felt on designated cells exhibiting these receptors. The insulin receptor is present on virtually all cells and at high concentrations on the cells of the liver, skeletal muscles, and adipose tissue. Stimulation of the insulin receptor with insulin is an essential element in carbohydrate metabolism and storage.[0003]Diabetics either lack suffi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): C07C309/34C12Q1/34C12Q1/48G01N33/58
CPCC07C309/34C12Q1/34C12Q1/48G01N33/582G01N2333/62G01N2333/72G01N2333/9121
Inventor SPORTSMAN, RICHARDVILLAR, HUGO O.KAUVAR, LAWRENCE M.SPEVAK, WAYNE R.
Owner TELIK INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products